Rajesh Pahwa (University of Kansas Medical Center) discusses the management of dyskinesia in Parkinson’s disease with a focus on amantadine (GOCOVRI™), the first and only FDA-approved medication for this indication.
1. What is the mechanism of action of amantadine in dyskinesia? (0:11)
2. What were the major findings of the two pivotal studies that led to the approval of GOCOVRI™ (amantadine) extended release capsules? (0:51)
3. Could you tell us a little about the pharmacokinetic profile of GOCOVRI™ and its recommended dosing regimen to achieve optimal dyskinesia control? (2:06)
4. How does the extended release formulation contribute to the tolerability of amantadine? (3:12)
5. What is the effect of GOCOVRI™ on non-motor symptoms in patients with Parkinson’s disease? (4:02)
Speaker disclosures: Rajesh Pahwa has received consulting fees from Abbvie, ACADIA, Acorda, Adamas, Cynapses, Global Kinetics, Lundbeck, Neurocrine, Pfizer, Sage, Sunovion, Teva Neuroscience, and US World Meds. Dr. Pahwa has received personal compensation in an editorial capacity as the Co-Editor-In-Chief of the International Journal of Neuroscience. Dr. Pahwa has received research support from Abbvie, Adamas, Avid, Biotie, Boston Scientific, Cala Health, Civitas, Cynapses, Kyowa, National Parkinson Foundation, NIH/NINDS, Parkinson Study Group, and Pfizer.
Filmed at the American Academy of Neurology (AAN) Annual Meeting 2018, Los Angeles, CA, US, April 2018.
Share this Video
Related Videos In Parkinson's Disease
Claudia Trenkwalder, EAN 2021: REM Sleep Behaviour Disorder and Neurodegeneration
touchNEUROLOGY was joined by Prof. Claudia Trenkwalder (Paracelsus-Elena-Hospital, Kassel Germany, University Medical Center, Goettingen, Germany) to discuss her EAN presentation looking into REM Sleep Behaviour Disorder and the connection with neurodegeneration. The abstract entitled: ‘REM Sleep Behaviour Disorder (RBD): future implications for neurodegenerative disease’ was presented at the 7th Congress of the European Academy of […]
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!